Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | TDO2 | P48775 | 4/20 | 0.37 |
| ▸ | IDO2 | Q6ZQW0 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL146073 | 0.99 | IDO1 (0.57) | IDO1HDAC1TDO2IDO2CYP3A4 | |
| SCHEMBL148261 | 0.94 | IDO1 (0.60) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL30589086 | 0.94 | IDO1 (0.60) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL29609373 | 0.93 | IDO1 (0.59) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| Iodide SCHEMBL145709 | 0.93 | IDO1 (0.59) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL148937 | 0.93 | IDO1 (0.59) | IDO1TDO2IDO2CYP3A4CYP2C9 | |
| SCHEMBL23066846 | 0.92 | IDO1 (0.56) | IDO1HDAC1TDO2IDO2 | |
| SCHEMBL146341 | 0.91 | IDO1 (0.55) | IDO1HDAC1TDO2IDO2 | |
| SCHEMBL22000381 | 0.90 | IDO1 (0.57) | IDO1HDAC1TDO2IDO2CYP3A4 | |
| SCHEMBL16709496 | 0.90 | IDO1 (0.56) | IDO1HDAC1TDO2IDO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617198-B1 | GUANIDINE DERIVATIVE | LUNAN PHARMACEUTICAL GROUP CORP (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| CN-109111438-B | Amidine compounds for IDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20200325109-A1 | IMINO-UREA DERIVATIVES | Carolina Cloud Exchange Inc. | 2020-10-15 | — | — | US | disclosed |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3617198-A1 | GUANIDINE DERIVATIVE | Lunan Pharmaceutical Group Corporation (CN) | 2020-03-04 | — | — | EP | disclosed |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-10034864-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-9789094-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160220543-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2016-08-04 | — | — | US | disclosed |
| US-9320732-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-8993605-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2014-10-23 | — | — | US | disclosed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-10034864-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-20200325109-A1 | IMINO-UREA DERIVATIVES | IDO2, IDO1, INMT | IDO1 2/4885HDAC1 2224/4885TDO2 15/4885 |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-20160220543-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885HDAC1 419/4885TDO2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.